Literature DB >> 31858533

MiR-195-5p inhibits the cell migration and invasion of cervical carcinoma through suppressing ARL2.

S-S Pan1, H-E Zhou, H-Y Yu, L-H Xu.   

Abstract

OBJECTIVE: MicroRNAs (miRNAs) have great effects on the progression of cervical cancer (CC). This study aimed to investigate the role of miR-195-5p in CC and to explain the regulatory mechanism between ARL2 and miR-195-5p. PATIENTS AND METHODS: Quantitative Real-Time-Polymerase Chain Reaction (qRT-PCR) was used to detect miR-195-5p levels in CC tissues and cell lines. Transwell assays for cell migration and invasion were also performed. A luciferase reporter assay was used to detect the direct target of miR-195-5p. The protein levels of ARL2 were measured by Western blot analysis.
RESULTS: In CC tissues and cell lines, miR-195-5p expression was decreased. Downregulation of miR-195-5p was associated with higher FIGO stage, deep stromal invasion, and lymph node metastasis. Moreover, over-expression of miR-195-5p inhibited cell migration and invasion in CC. Furthermore, it was observed that miR-195-5p directly targeted ARL2, which affected the suppressive effect of miR-195-5p in CC.
CONCLUSIONS: MiR-195-5p inhibited cell migration and invasion in CC by suppressing ARL2 expression. The miR-195/ARL2 axis may provide a pathway for cell metastasis in CC.

Entities:  

Year:  2019        PMID: 31858533     DOI: 10.26355/eurrev_201912_19764

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  10 in total

1.  Relationship between M6A methylation regulator and prognosis in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.

Authors:  Deliang Huang; Dejing Huang
Journal:  Heliyon       Date:  2022-10-07

2.  Circ_0084927 Facilitates Cervical Cancer Development via Sponging miR-142-3p and Upregulating ARL2.

Authors:  Liquan Chen; Xiaowei Zhang; Su Wang; Xiaoting Lin; Lizhen Xu
Journal:  Cancer Manag Res       Date:  2020-09-28       Impact factor: 3.989

3.  Hsa_circ_0060937 accelerates non-small cell lung cancer progression via modulating miR-195-5p/HMGB3 pathway.

Authors:  Junfeng Xi; Yunfeng Xi; Zhibin Zhang; Yanhong Hao; Fei Wu; Burong Bian; Guangjun Hao; Weiwei Li; Shuqun Zhang
Journal:  Cell Cycle       Date:  2021-09-01       Impact factor: 5.173

4.  Effect of miR-195-5p on cardiomyocyte apoptosis in rats with heart failure by regulating TGF-β1/Smad3 signaling pathway.

Authors:  Chun Xie; Huaxin Qi; Lei Huan; Yan Yang
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.840

5.  LncRNA PVT1 promotes cervical cancer progression by sponging miR-503 to upregulate ARL2 expression.

Authors:  Weiwei Liu; Dongmei Yao; Bo Huang
Journal:  Open Life Sci       Date:  2021-01-21       Impact factor: 0.938

6.  LncRNA LIPE-AS1 Predicts Poor Survival of Cervical Cancer and Promotes Its Proliferation and Migration via Modulating miR-195-5p/MAPK Pathway.

Authors:  Jie Zhang; Pinping Jiang; Shoyu Wang; Wenjun Cheng; Shilong Fu
Journal:  Front Oncol       Date:  2021-04-09       Impact factor: 6.244

7.  MiR-195-5p Ameliorates Cerebral Ischemia-Reperfusion Injury by Regulating the PTEN-AKT Signaling Pathway.

Authors:  Xiaoli Ren; Zhiyun Wang; Congfang Guo
Journal:  Neuropsychiatr Dis Treat       Date:  2021-04-29       Impact factor: 2.570

8.  Lack of Conserved miRNA Deregulation in HPV-Induced Squamous Cell Carcinomas.

Authors:  Jaroslav Nunvar; Lucie Pagacova; Zuzana Vojtechova; Nayara Trevisan Doimo de Azevedo; Jana Smahelova; Martina Salakova; Ruth Tachezy
Journal:  Biomolecules       Date:  2021-05-20

9.  Bioinformatics Analysis and Identification of Underlying Biomarkers Potentially Linking Allergic Rhinitis and Asthma.

Authors:  Zhanfeng Yan; Lili Liu; Lulu Jiao; Xiaohui Wen; Jianhua Liu; Ningyu Wang
Journal:  Med Sci Monit       Date:  2020-05-27

10.  hsa-miR-195-5p inhibits cell proliferation of human thyroid carcinoma cells via modulation of p21/cyclin D1 axis.

Authors:  Dexin Liu; Ping Li; Xiaodong Wang; Wei Wang
Journal:  Transl Cancer Res       Date:  2020-09       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.